SakhiHMoktefiABouachiK, et al.Podocyte injury in lupus nephritis. J Clinical Medicine2019; 8: 1340.
2.
Oliva-DamasoNPayanJOliva-DamasoE, et al.Lupus podocytopathy: an overview. Advances Chronic Kidney Disease2019; 26: 369–375.
3.
HanTSSchwartzMMLewisEJ. Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus2006; 15: 71–75.
4.
DubeGKMarkowitzGSRadhakrishnanJ, et al.Minimal change disease in systemic lupus erythematosus. Clinical Nephrology2002; 57: 120–126.
5.
Rafael-VidalCAltabásIPérezN, et al.Calcineurin and systemic lupus erythematosus: the rationale for using calcineurin inhibitors in the treatment of lupus nephritis. International J Molecular Sciences2021; 22: 1263.
6.
ArriensCPolyakovaSAdzerikhoI, et al.Aurora Phase 3 Study demonstrates voclosporin statistical superiority over standard of care in Lupus Nephritis (LN). Annals of the Rheumatic Diseases2020; 75: 819. https://ard.bmj.com/content/79/Suppl_1/172.2 (accessed on 19 December 2020).
